Acadia Pharma (ACAD) Tops Q4 EPS by 64c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $28.93 --0%
EPS Growth %: -52.4%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
VIVO, PMCB, PLCE, More
EPS Growth %: -52.4%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of $0.86, $0.64 better than the analyst estimate of $0.22. Revenue for the quarter came in at $259.6 million versus the consensus estimate of $271.64 million.
GUIDANCE:
Acadia Pharma sees FY2025 revenue of $1.03-1.09 billion, versus the consensus of $1.05 billion.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toro Company (TTC) Tops Q3 EPS by 3c; offers guidance
- BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18
- Brady Corp. (BRC) Tops Q4 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
